DMF significantly reduced the odds of having a higher number of gadolinium-enhancing lesions by 88 % ( BID ) and 75 % ( TID ) and the mean number of new or enlarging T2 lesions by 72 % ( BID ) and 67 % ( TID ) , from the first post-baseline magnetic resonance imaging assessment at 24weeks ( all P < 0.0001 versus placebo ) .